VTVT
vTv Therapeutics, Inc. Class A · NASDAQ
- Sector Health Technology
- Industry Pharmaceuticals: Major
- Website vtvtherapeutics.com
- Employees(FY) 13
- ISIN US9183852048
Performance
+3.99%
1W
+15.62%
1M
+189.8%
3M
+92.63%
6M
+142.61%
YTD
-26.37%
1Y
Profile
vTv Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on the development of orally administered treatments for diabetes. The company's lead drug candidate is TTP399, an orally administered, small molecule, and liver-selective glucokinase activator for the treatment of type 1 diabetes; and HPP737, an orally administered non-CNS penetrant phosphodiesterase type 4 (PDE4) inhibitor that addresses inflammatory diseases and psoriasis. It is also involved in the clinical development of other programs, including TTP273, an oral small molecule GLP-1 receptor agonist for postprandial glucose excursion to treat cystic fibrosis related diabetes; HPP3033, a non-electrophilic therapeutic approach to activating the Nrf2 pathway for the treatment of chronic diseases associated with oxidative stress; azeliragon, a RAGE antagonist for inflammatory lung diseases, including severe COVID-19, as well as for pancreatic and breast cancers; and HPP971, an Nrf2 activator. vTv Therapeutics Inc. has a license agreement with Reneo Pharmaceuticals, Inc. to develop and commercialize peroxisome proliferation activated receptor delta agonist program, including the compound HPP593; and license and research agreements with Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.; Newsoara Biopharma Co., Ltd.; JDRF International; and Novo Nordisk A/S. The company was incorporated in 2015 and is headquartered in High Point, North Carolina. vTv Therapeutics Inc. is a subsidiary of MacAndrews & Forbes Incorporated.
Technical Analysis of VTVT 2024-05-10
Overview:
In analyzing the technical indicators for VTVT over the last 5 days, we will delve into the trend, momentum, volatility, and volume indicators to provide a comprehensive outlook on the possible stock price movement in the coming days.
Trend Analysis:
- Moving Averages (MA): The 5-day MA has been fluctuating around the 25.50 level, indic...
Recent News & Updates
- 2024-05-09 10:57
- 2024-05-09 05:02
VTv Therapeutics: Q1 Earnings Snapshot(Yahoo Finance)
- 2024-05-09 04:51
- 2024-03-18 20:30
- 2024-03-12 20:24
VTv Therapeutics: Q4 Earnings Snapshot(Yahoo Finance)
- 2024-03-12 20:00
- 2024-03-04 02:49
The Top 3 Healthcare Stocks to Buy on Weakness in 2024(Yahoo Finance)
- 2024-03-03 19:00
- 2024-02-29 19:00
- 2024-02-27 19:00
- 2024-02-22 03:00
- 2023-11-09 04:06
VTv Therapeutics: Q3 Earnings Snapshot(Yahoo Finance)
- 2023-11-09 03:30
- 2023-11-07 19:00
- 2023-11-01 20:00
- 2023-10-31 20:00
- 2023-09-26 20:30
- 2023-09-25 20:30
- 2023-09-21 17:22
3 Tumbling Stocks to Take a Chance On Now(Yahoo Finance)
- 2023-09-17 20:30
- 2023-08-24 00:35
Is vTv Therapeutics Inc (VTVT) Modestly Undervalued?(Yahoo Finance)
- 2023-08-16 02:44
- 2023-08-11 04:37
VTv Therapeutics: Q2 Earnings Snapshot(Yahoo Finance)
- 2023-08-11 04:30
- 2023-08-09 20:33
- 2023-06-15 20:00
- 2023-06-14 19:33
- 2023-05-23 21:00
- 2023-05-11 20:11
vTv Therapeutics Insider Ups Holding During Year \(Yahoo Finance)
- 2023-05-11 04:33
VTv Therapeutics: Q1 Earnings Snapshot(Yahoo Finance)
Page 1 of 4
previousnext